Regeneron's Phase 2 COURAGE trial shows trevogrumab prevents 70% of muscle loss in obesity patients treated with semaglutide. The findings were presented at the European Association for the Study of Diabetes (EASD) Annual Meeting and are in press with The Lancet.
TL;DR
- Trevogrumab, developed by Regeneron, has shown promising results in preserving muscle mass in obesity patients undergoing weight loss treatment with semaglutide.
- The Phase 2 COURAGE trial demonstrated that trevogrumab prevented 70% of muscle loss associated with semaglutide treatment.
- These findings could significantly impact the treatment of obesity, particularly for patients at risk of sarcopenia and muscle loss.
What happened
Regeneron Pharmaceuticals announced results from the Phase 2 COURAGE trial, which evaluated trevogrumab's potential to prevent lean mass and muscle loss during GLP-1 receptor agonist-induced weight loss in obesity patients.
The trial found that trevogrumab, when combined with semaglutide, preserved nearly 70% of the thigh muscle that would have been lost with semaglutide treatment alone.
The results were presented at the European Association for the Study of Diabetes (EASD) Annual Meeting and are in press with The Lancet.
Why it matters
These findings are significant for obesity treatment, as GLP-1 receptor agonists like semaglutide can cause muscle loss, which is a concern for patients with sarcopenia and older adults.
Trevogrumab's ability to preserve muscle mass could enhance the quality of weight loss in obesity patients, addressing a critical gap in current treatments.
Regeneron plans to initiate a Phase 2 trial evaluating trevogrumab in combination with GLP-1 receptor agonist-based therapies in older adults with obesity and decreased muscle mass and/or strength.
Key facts
- Trevogrumab prevented 70% of muscle loss associated with semaglutide treatment, according to the Phase 2 COURAGE trial.
- The trial included 52 weeks of treatment and evaluated both higher-dose and lower-dose portions of trevogrumab in combination with semaglutide.
- Trevogrumab preserved lean mass at both 26 and 52 weeks compared to placebo, with the greatest reduction in lean mass occurring during the first six months of treatment.
- The lower doses of trevogrumab were generally well tolerated, with 77% of participants experiencing at least one adverse event.
- Regeneron plans to initiate a Phase 2 trial evaluating trevogrumab in combination with GLP-1 receptor agonist-based therapies in older adults with obesity and decreased muscle mass and/or strength.
Context
Obesity is a complex, multifaceted disease affecting over a billion people worldwide. While GLP-1 receptor agonists like semaglutide have revolutionized weight loss treatments, they can cause significant muscle loss.
Trevogrumab, developed by Regeneron, targets myostatin, a protein that inhibits muscle growth. By blocking myostatin, trevogrumab aims to preserve muscle mass during weight loss.
The Phase 2 COURAGE trial results suggest that trevogrumab could play a crucial role in improving the quality of weight loss in obesity patients, particularly those at risk of sarcopenia and muscle loss.